StockData

Puma Biotechnology vs Zymeworks

PBYI and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PBYI and ZYME compare

Zymeworks is the larger company, worth 5.0 times as much as Puma Biotechnology ($1.9B against $379M).

Puma Biotechnology grew revenue faster over the last twelve months (−2.9% versus −69.8% for Zymeworks).

Puma Biotechnology keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −404% at Zymeworks.

Puma Biotechnology scores higher on the StockData Score (14 against 5 for Zymeworks), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPBYIZYME
Size and price
Market cap$379M$1.9B
Share price$7.34$26.45
Change, 1 year48.3%43.0%
Change, 5 years128%35.6%
Beta (5Y)1.280.28
Employees179264
StockData Score
Total score14 (better)5
Valuation score2 (better)0
Growth score2 (better)0
Performance score5 (better)0
Health score55
Dividend score00
Valuation
P/E14.1×–
P/S1.6× (better)50.6×
P/B2.7× (better)23.4×
EV/EBITDA7.1×–
P/FCF9.2×–
FCF yield10.9% (better)−6.4%
Fair value$8.88$3.39
Margin of safety17.4% (better)−680%
Growth
Revenue growth (TTM)−2.9% (better)−69.8%
Revenue growth, 5Y average0.29%22.2% (better)
Net income growth (TTM)−44.9%–
EPS growth (TTM)−46.9%–
Profitability
Gross margin74.8%–
Operating margin13.2% (better)−419%
Net margin11.6% (better)−404%
FCF margin17.8% (better)−325%
Return on equity22.0% (better)−72.3%
Return on invested capital42.7% (better)−179%
Financial health
Debt / equity0.000.00
Net debt / EBITDA−2.12–
Interest coverage8.6×–
Current ratio2.916.32 (better)
Altman Z-score−2.78−1.01 (better)
Piotroski F-score8 (better)6
Dividends and buybacks
Buyback yield–9.0%
Shareholder yield0.00%9.0% (better)
Ownership
Held by institutions74.9%98.1%
Held by insiders18.9%58.9%
Insider net buying, 12 months−$2.1M (better)−$5.0M
Short interest, % of float10.3%20.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.